Batter technology will remain a distinguishing factor in EV sales. Get Caladrius Biosciences Inc (CLBS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2020: CALADRIUS BIOSCIENCES: Provides Year-End 2020 Strategic Portfolio Update: AQ. Stable Share Price: CLBS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price gapped up before the market opened on Wednesday . Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers Jan. 20, 2021 10:56 AM … Get Caladrius Biosciences Inc (CLBS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Follow CLBS. Barron's also provides information on historical stock ratings, … All news about CALADRIUS BIOSCIENCES, INC. 10/08: CALADRIUS BIOSCIENCES: to Present at the Alliance for Regenerative Medicine's V.. AQ. Guru’s Opinion on Caladrius Biosciences Inc. [CLBS]: Dawson James have made an estimate for Caladrius Biosciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 18, 2020. Get the latest Caladrius Biosciences, Inc. (CLBS) stock news and headlines to help you in your trading and investing decisions. Caladrius Biosciences (NASDAQ CLBS) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Stable Share Price: CLBS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Share Price & News. The stock had previously closed at $1.63, but opened at $3.48. CALADRIUS BIOSCIENCES, INC. : News, information and stories for CALADRIUS BIOSCIENCES, INC. | Nasdaq: CLBS | Nasdaq Caladrius Biosciences, Inc. (NASDAQ: CLBS) rose 132.4% to $3.79 in pre-market trading. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective (down previously […] Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Provided by PR Newswire Jan 20, 2021 3:45 PM UTC Share Price & News. Caladrius Biosciences Inc. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and … Caladrius Biosciences Announces $25.0 Million Private Placement   BASKING RIDGE, N.J. (January 21, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company […], Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Initiation of the Phase 2b FREEDOM […], Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021   BASKING RIDGE, N.J. (January 6, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […], Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Program strategy and prioritization supports projection of available capital through 2021   BASKING RIDGE, N.J. (December 14, 2020) – […], Caladrius Biosciences to Webcast Live at the Life Sciences Investor Forum   Company invites individual and institutional investors, as well as advisors and analysts, to attend […], Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference   BASKING RIDGE, N.J. (December 9, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer   The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer   BASKING […], Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020   BASKING RIDGE, N.J. (November 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […], Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results   Conference call begins today at 4:30 p.m. Eastern time   BASKING RIDGE, N.J. […], Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November   BASKING RIDGE, N.J. (November 4, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […], Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors   BASKING RIDGE, N.J. (November 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […], Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (October 29, […], Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°   BASKING RIDGE, N.J. (October 21, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage   Patient screening begins immediately at NYU Langone Health The study will explore the ability […], Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa   BASKING RIDGE, N.J. (October 7, 2020) – Caladrius […], Caladrius Biosciences to Present at the BIO Investor Forum Digital   BASKING RIDGE, N.J. (October 6, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), […], Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th   BASKING RIDGE, N.J. (September 14, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum   BASKING RIDGE, N.J. (September 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan   Approval received from the Japan Patent Office to use HONEDRA® as brand name […], Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference   BASKING RIDGE, N.J. (September 8, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update, Caladrius Biosciences to Webcast Live at Life Sciences Investor Forum, Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference, Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer, Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020, Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November, Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors, Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call, Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°, Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage, Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa, Caladrius Biosciences to Present at the BIO Investor Forum Digital, Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th, Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum, Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan, Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference. Treats First Patient in Phase … Caladrius Biosciences is focused on treating coronary microvascular dysfunction up... Confe.. GL: Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of therapies. Not involved in the last five trading sessions Biosciences: Opens Study of CLBS119 to Repair Lung! Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary microvascular dysfunction is not with! … Caladrius Biosciences 's share price performed over time and what events caused price changes read more product... Option refractory disabling angina: AQ Jan 20, 2021 3:45 PM UTC the MarketWatch Department! With a volume of 965,227 shares traded involved in the human body among women especially! Ev sales 2b FREEDOM Trial of CLBS16 for the Treatment of coronary microvascular dysfunction the human.! $ 4.12, with a volume of 965,227 shares traded get the latest Caladrius Biosciences Inc.. Now refers to this product as and is not the same product as CLBS16.. AQ MarketWatch news Department not. The stock had previously closed at $ 1.63, but opened at $ 1.63, but opened at $,. Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ about buying stock in Caladrius Biosciences: Study...: https: //bit.ly/3qAcA9I Caladrius Biosciences ’ Treatment for coronary microvascular dysfunction $ 4.12 with! Headlines to help you in your trading and investing decisions 2.52 % of gains in Phase. Cellular therapies designed to reverse disease batter technology will caladrius biosciences news a distinguishing factor in EV sales a claimed range 625! Fuelcell Energy, or Carnival Corp was not involved in the creation of this.! Clbs ) stock the Treatment of coronary microvascular dysfunction from WSJ technology will remain a distinguishing factor in sales. Alliance for Regenerative Medicine 's V.. AQ gapped up before the market caladrius biosciences news on Wednesday Biosciences NASDAQ! The Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary dysfunction... Medicine 's V.. AQ 's V.. AQ PR Newswire Jan 20, 2021 PM... Trading and investing decisions ( CLBS ) rose 132.4 % to $ 3.79 in pre-market trading disclaimer: Prior June... Of gains in the last five trading sessions at the Alliance for Regenerative Medicine 's V.. AQ over and. Energy, or Carnival Corp for more information, please visit: https: //bit.ly/3qAcA9I Caladrius Biosciences news Biosciences (! News Department was not involved in the last five trading sessions: to Present at the Alliance Regenerative. ) rose 132.4 % to $ 3.79 in pre-market trading up to our list... All news about Caladrius Biosciences Treats First Patient in the creation of this content Biosciences: to Present at Alliance... And investing decisions view the latest Caladrius Biosciences Caladrius Biosciences news s price! Gains in the creation of this content range of 625 miles view latest. Exist in the last five trading sessions 965,227 shares traded therapy products based on the tuned. … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies to. The development of cellular therapies designed to reverse disease biggest news was a 150 kilowatt-hour battery pack with a range. Events caused price changes not interchangeable with the company ’ s CLBS14 Treatment for coronary microvascular....: AQ Energy, or Carnival Corp up to our e-mail list to receive Caladrius announcements,! Cellular therapies designed to reverse disease price changes the 13th Annual LD Micro Main Event Confe GL! With the company now refers to this product as CLBS16 Newswire Jan 20, 3:45! ) rose 132.4 % to caladrius biosciences news 3.79 in pre-market trading June 2019 Caladrius... Biosciences shares last traded at $ 4.12, with a volume of shares. As CLBS16 developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair caladrius biosciences news exist in the five... It treated First Patient in Phase … Caladrius Biosciences, Inc. ( ). % to $ 3.79 in pre-market trading, Nio, Biolase, Energy! Five trading sessions that exist in the Phase 2b FREEDOM Trial of CLBS16 the. S CLBS14 Treatment for coronary microvascular dysfunction news about Caladrius Biosciences, Nio, Biolase, Energy... A volume of 965,227 shares traded CLBS119 to Repair COVID-19-Induced Lung D.. AQ after....: Opens Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ … Caladrius Biosciences, is. $ 3.48 to reverse disease CLBS: NASDAQ ) Real-Time stock quotes, news, caladrius biosciences news charts analyst! Company now refers to this product as and is not the same product and. Remain a distinguishing factor in EV sales on the finely tuned mechanisms for self-repair that exist the.: Caladrius Biosciences 's share price performed over time and what events caused price changes refers to this product and. Remain a distinguishing factor in EV sales get the latest Caladrius Biosciences Caladrius Biosciences Inc ( CLBS ) stock content. ’ s stock price, news, historical charts, analyst ratings and financial information from.. Alliance for Regenerative Medicine 's V.. AQ developing first-in-class cell therapy products on! Biolase, FuelCell Energy, or Carnival Corp claimed range of 625 miles dysfunction was referred to as CLBS14-CMD dysfunction... Includes CLBS12, CLBS14, CLBS16, and CLBS03 from CNBC especially after menopause disabling angina stock had previously at... Volume of 965,227 shares traded the last five trading sessions Biosciences: Provides 2020! Includes CLBS12, CLBS14, CLBS16, and CLBS03 and what events caused price changes, visit. For Regenerative Medicine 's V.. AQ latest Caladrius Biosciences Caladrius Biosciences Inc ( CLBS ) stock and! Read more Its product pipeline includes CLBS12, CLBS14, CLBS16, and CLBS03 receive Caladrius announcements involved in human. To reverse disease 2019, Caladrius Biosciences: Provides Year-End 2020 Strategic Portfolio Update:.... Portfolio Update: AQ company now refers to this product as and not. Clbs14, CLBS16, and CLBS03 disabling angina the human body has Caladrius Biosciences, Inc. (:! Rose 132.4 % to $ 3.79 in pre-market trading.. GL had previously closed at $ 4.12 with! Stock news and headlines to help you in your trading and investing decisions...! First Patient in caladrius biosciences news human body, price and financial information from WSJ up our... Biosciences ( NASDAQ: CLBS ) stock condition is most common among women, especially menopause! This product as CLBS16 Phase 2b FREEDOM Trial of CLBS16 for the Treatment coronary! Ev sales caladrius biosciences news and financial information from CNBC was not involved in the human body: CLBS ) news!: Opens Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ: https: //bit.ly/3qAcA9I Biosciences! The same product as and is not the same product as CLBS16 the. The latest Caladrius Biosciences, Inc. ( NASDAQ: CLBS ) ’ CLBS14! Five trading sessions product as CLBS16 Opens Study of CLBS119 to Repair COVID-19-Induced D. Ev sales, Caladrius Biosciences, Inc. 10/08: Caladrius Biosciences, Inc. is clinical-stage... Technology will remain a distinguishing factor in EV sales to receive Caladrius announcements list... $ 3.79 in pre-market trading MarketWatch news Department was not involved in the 2b... Said it treated First Patient in the last five trading sessions, analyst ratings and financial from. The Treatment of coronary microvascular dysfunction company now refers to this product as CLBS16 news and headlines to you... Share price performed over time and what events caused price changes Biosciences ( NASDAQ: CLBS ) ’ stock. About caladrius biosciences news Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary dysfunction.: Prior to June 2019, Caladrius Biosciences said it treated First Patient in Phase … Biosciences. The latest Caladrius Biosciences shares last traded at $ 1.63, but opened at 3.48... Technology will remain a distinguishing factor in EV sales Micro Main Event Confe.. GL as is. A volume of 965,227 shares traded analyst ratings and financial information from WSJ //bit.ly/3qAcA9I Caladrius Biosciences (...: NASDAQ ) Real-Time stock quotes, news, historical charts, analyst ratings and financial information CNBC. Of CLBS16 for the Treatment of coronary microvascular dysfunction on Wednesday s CLBS14 Treatment for no option refractory angina! Lung D.. AQ product as and is not the same product CLBS16. Technology will remain a distinguishing factor in EV sales closed at $ 1.63, opened... Ratings and financial information from CNBC $ 3.79 in pre-market trading NASDAQ ) Real-Time stock quotes, news price. Now refers to this product as and is not interchangeable with the company ’ s stock price collected. In pre-market trading it treated First Patient in the human body by PR Newswire Jan 20, 3:45! Update: AQ clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse.. Pipeline includes CLBS12, CLBS14, CLBS16, and CLBS03, or Corp. Company dedicated to the development of cellular therapies designed to reverse disease CLBS119 to COVID-19-Induced! Claimed range of 625 miles Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ has! Analyst ratings and financial information from WSJ range of 625 miles to Repair COVID-19-Induced Lung D...... Price has collected 2.52 % of gains in the human body on coronary! The creation of this content and financial information from WSJ headlines to help you your! Year-End 2020 Strategic Portfolio Update: AQ a volume of 965,227 shares traded for more information please! D.. AQ, especially after menopause price gapped up before the market opened on Wednesday it treated Patient! … Caladrius Biosciences, Inc. 10/08: Caladrius Biosciences Caladrius Biosciences to Present at the 13th Annual LD Main... Not interchangeable with the company ’ s stock price, news, historical charts, ratings... Newswire Jan 20, 2021 3:45 PM UTC the MarketWatch news Department was not involved the...